全文获取类型
收费全文 | 4344篇 |
免费 | 445篇 |
国内免费 | 100篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 211篇 |
妇产科学 | 149篇 |
基础医学 | 529篇 |
口腔科学 | 70篇 |
临床医学 | 555篇 |
内科学 | 1269篇 |
皮肤病学 | 34篇 |
神经病学 | 215篇 |
特种医学 | 174篇 |
外国民族医学 | 1篇 |
外科学 | 840篇 |
综合类 | 80篇 |
一般理论 | 2篇 |
预防医学 | 237篇 |
眼科学 | 57篇 |
药学 | 188篇 |
肿瘤学 | 232篇 |
出版年
2019年 | 52篇 |
2018年 | 50篇 |
2017年 | 65篇 |
2016年 | 53篇 |
2015年 | 44篇 |
2014年 | 88篇 |
2013年 | 133篇 |
2012年 | 122篇 |
2011年 | 139篇 |
2010年 | 100篇 |
2009年 | 84篇 |
2008年 | 130篇 |
2007年 | 182篇 |
2006年 | 152篇 |
2005年 | 181篇 |
2004年 | 128篇 |
2003年 | 114篇 |
2002年 | 105篇 |
2001年 | 130篇 |
2000年 | 113篇 |
1999年 | 104篇 |
1998年 | 79篇 |
1997年 | 69篇 |
1996年 | 49篇 |
1995年 | 54篇 |
1994年 | 63篇 |
1993年 | 65篇 |
1992年 | 87篇 |
1991年 | 88篇 |
1990年 | 99篇 |
1989年 | 115篇 |
1988年 | 111篇 |
1987年 | 82篇 |
1986年 | 113篇 |
1985年 | 106篇 |
1984年 | 78篇 |
1983年 | 80篇 |
1982年 | 49篇 |
1981年 | 46篇 |
1980年 | 48篇 |
1979年 | 67篇 |
1978年 | 69篇 |
1977年 | 55篇 |
1976年 | 53篇 |
1975年 | 67篇 |
1974年 | 78篇 |
1973年 | 67篇 |
1972年 | 62篇 |
1970年 | 46篇 |
1967年 | 48篇 |
排序方式: 共有4889条查询结果,搜索用时 0 毫秒
81.
Spencer H. Kubo Thomas S. Rector John E. Strobeck Jay N. Cohn 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1988,2(5):653-660
Summary To characterize the effects of OPC-8212, a quinolone inotropic agent, in patients with heart failure, we utilized invesive homodynamics, exercise testing, 24-hour ambulatory electrocardiograms, and two patient self-assessment questionnaires, before and after 1 month of treatment with OPC-8212, in 17 patients with moderate to severe congestive heart failure. There were no significant changes from baseline in heart rate (83±8 beats/min), mean arterial pressure (70±15 mmHg), pulmonary wedge pressure (18±7 mmHg), or cardiac index (2.3±0.4 L/min/m2) following treatment with OPC-8212. Both exercise duration (5.3±1.6 min) and peak oxygen consumption (12.0±2.9 mL/kg/min) were unchanged by OPC-8212. Two independent patient self-assessment scores, the Sickness Impact Profile and the Minnesota Living with Heart Failure Questionnaire, showed improvements from 6.8 to 5.4 and 49 to 38, respectively (both p<.05), suggesting that the patients reported an improvement in daily functioning. The median ventricular premature contraction count and frequency were reduced from 1,118 beats to 243 beats (p<0.05) and 11/1,000 beats to 2,4/1,000 beats (0.05<p<0.10), respectively. Two patients developed agranulocytosis during longer-term treatment following this 1-month study. These data demonstrate that OPC-8212 did not have significant effects on hemodynamics or exercise tolerance. However, the improvement in patient self-assessment scores and the trend for improvement in ventricular arrhythmia profiles suggest that OPC-8212 may have some benefit for patients with congestive heart failure, but additional placebo-controlled, double-blind studies are necessary. 相似文献
82.
Serum osteocalcin and total body calcium in normal pre- and postmenopausal women and postmenopausal osteoporotic patients 总被引:1,自引:0,他引:1
S Yasumura J F Aloia C M Gundberg J Yeh A N Vaswani K Yuen A F Lo Monte K J Ellis S H Cohn 《The Journal of clinical endocrinology and metabolism》1987,64(4):681-685
Serum osteocalcin was measured in 51 normal pre- and 114 postmenopausal women and in 41 postmenopausal osteoporotic patients. Total body calcium (TBCa) was determined in the same individuals by neutron activation analysis. Many of the perimenopausal nonosteoporotic women had increased serum osteocalcin values, but 15 yr or more after the menopause most of the women had serum osteocalcin levels in the normal range. Comparing normal women before and after menopause, the mean serum osteocalcin levels [7.8 +/- 4.7 (+/- SE) and 10.1 +/- 9.4 ng/mL] were not significantly different; however, the TBCa values (898 +/- 99 and 806 +/- 111 g) were significantly different (P less than 0.001). When the normal postmenopausal women were regrouped according to high vs. low osteocalcin values, TBCa and phosphorus content as well as forearm linear bone density were significantly lower in the high osteocalcin group, even though most of the other variables, including urinary hydroxyproline excretion, serum alkaline phosphatase, age, height, and weight, were not different. Osteoporotic women had a mean serum osteocalcin concentration of 17.4 +/- 8.6 ng/ml and a TBCa of 657 +/- 83 g, both significantly different from the respective values in normal and pre- and postmenopausal women (P less than 0.001 for both variables in comparison to each group). These data suggest that high serum osteocalcin levels, at least on a group basis, are an index of low skeletal mass. 相似文献
83.
84.
85.
Cohn JN 《Nature clinical practice. Cardiovascular medicine》2008,5(9):526-527
ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan and the angiotensin-converting-enzyme (ACE) inhibitor ramipril, caution should be exercised in assuming that the mean response in a clinical trial applies to individual patients who might benefit from combination therapy. Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other. 相似文献
86.
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial 总被引:1,自引:0,他引:1
Silverman MH Strand V Markovits D Nahir M Reitblat T Molad Y Rosner I Rozenbaum M Mader R Adawi M Caspi D Tishler M Langevitz P Rubinow A Friedman J Green L Tanay A Ochaion A Cohen S Kerns WD Cohn I Fishman-Furman S Farbstein M Yehuda SB Fishman P 《The Journal of rheumatology》2008,35(1):41-48
OBJECTIVE: Adenosine exerts antiinflammatory effects via activation of the A3 adenosine receptor (A3AR), a Gi protein-associated cell-surface receptor, overexpressed in synovial tissue and peripheral blood mononuclear cells (PBMC) in patients with active rheumatoid arthritis (RA). CF101 is a highly specific orally bioavailable A3AR agonist. METHODS: This was a multicenter study, blinded to dose, designed to assess the clinical activity and safety of CF101 in active RA. Seventy-four patients were randomized to receive 0.1, 1.0, or 4.0 mg CF101 bid for 12 weeks. The primary efficacy endpoint was American College of Rheumatology 20% response (ACR20) at Week 12. A3AR expression levels were analyzed in PBMC from 18 patients. RESULTS:. Maximal responses were observed with 1.0 mg bid, lower at 0.1 and 4.0 mg bid. At 12 weeks, 55.6%, 33.3%, and 11.5% of the patients receiving 1.0 mg CF101 achieved ACR20%, 50%, and 70% responses, respectively. CF101 was generally well tolerated, with mild headache (4.1%), nausea (2.7%), and rash (2.7%) being the most common treatment-related adverse events. Statistically significant correlations between A3AR overexpression at baseline and ACR50 and ACR70 responses were observed. CONCLUSION: CF101 administered bid for 12 weeks resulted in improvement in signs and symptoms of RA that did not achieve statistical significance, and was safe and well tolerated. The expression level of A3AR was directly correlated with patient responses to CF101, suggesting its utilization as a biomarker for the pharmacodynamic and therapeutic effects of this novel agent. These findings require confirmation in a double-blind randomized placebo-controlled trial, currently under way. 相似文献
87.
88.
89.
Marvin A. Konstam John Idoine Joshua Wynne William Grossman Lawrence Cohn J.Robert Beck Joseph Kozlowski B.Leonard Holman 《The American journal of cardiology》1983,51(7):1144-1148
Using equilibrium (gated) radionuclide ventriculography, right ventricular (RV) function was studied in 22 adults with pulmonary hypertension and in 16 patients without evidence of cardiac disease. To assess the effect of volume overload on RV performance in pulmonary hypertension, RV ejection fractions were compared in patients with and without left-to-right shunts due to atrial septal defect (ASD). In addition, the effect of ASD repair on RV function was examined. In 14 patients with pulmonary hypertension without RV volume overload (group I), the RV ejection fraction (0.35 ± 0.11, mean ± standard deviation [SD]) was significantly lower than in the normal group (0.47 ± 0.11, p < 0.01). In 8 patients with left-to-right shunts due to ASD (group II) and with RV systolic pressures similar to those in group I, the mean RV ejection fraction (0.53 ± 0.15) was normal and was significantly higher than in group I (p < 0.01). Right ventricular end-diastolic volumes, estimated from combined radionuclide and hemodynamic data, were higher (p < 0.01) in group II patients (171 ± 70 ml/m2) than in group I patients (70 ± 13 ml/m2). In 5 patients who underwent isolated shunt repair, mean RV ejection fraction decreased postoperatively from 0.57 ± 0.17 to 0.40 ± 0.12 (p < 0.05). It is concluded that (1) pulmonary hypertension frequently causes a decrease in RV systolic function due to abnormal afterload; (2) in patients with RV volume overload due to left-to-right shunt, systolic function, as measured by the ejection fraction, remains normal despite pulmonary hypertension, possibly through the Starling mechanism; and (3) RV systolic function often decreases after repair of an ASD. 相似文献
90.
Gregoric ID Cohn WE Akay MH La Francesca S Myers T Frazier OH 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2008,35(2):184-185
The CentriMag left ventricular assist system can be used for perioperative or postcardiotomy circulatory support of the failing heart. The device resides at the patient's bedside, and the cannulae are usually inserted through a midline sternotomy, with the inflow cannula in the left ventricle or right superior pulmonary vein and the outflow cannula in the aorta. In a patient whose chest has been closed and who has a delayed need for temporary mechanical support, a less invasive method of left ventricular assist device cannula insertion is preferred. In these cases, the CentriMag cannulae can be inserted through a right minithoracotomy with the inflow cannula in the right superior pulmonary vein and the outflow cannula in the aorta, with no heparinization. Herein, we describe this approach in a patient who experienced postcardiotomy cardiogenic shock after aortocoronary bypass surgery. This technique may facilitate ambulation and recovery in selected patients. 相似文献